Forsta AP Fonden Increases Stock Position in Cencora, Inc. (NYSE:COR)

Forsta AP Fonden lifted its holdings in shares of Cencora, Inc. (NYSE:COR) by 9.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 69,270 shares of the company’s stock after acquiring an additional 5,700 shares during the period. Forsta AP Fonden’s holdings in Cencora were worth $15,591,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. Parcion Private Wealth LLC grew its position in shares of Cencora by 90.9% during the third quarter. Parcion Private Wealth LLC now owns 1,791 shares of the company’s stock worth $403,000 after acquiring an additional 853 shares during the last quarter. Louisiana State Employees Retirement System grew its position in shares of Cencora by 4.3% during the third quarter. Louisiana State Employees Retirement System now owns 9,800 shares of the company’s stock worth $2,206,000 after acquiring an additional 400 shares during the last quarter. Allworth Financial LP grew its position in shares of Cencora by 22.8% during the third quarter. Allworth Financial LP now owns 1,672 shares of the company’s stock worth $376,000 after acquiring an additional 310 shares during the last quarter. Lincoln Capital Corp grew its position in Cencora by 1.1% in the 3rd quarter. Lincoln Capital Corp now owns 23,258 shares of the company’s stock valued at $5,235,000 after buying an additional 247 shares during the last quarter. Finally, Sigma Investment Counselors Inc. grew its position in Cencora by 0.8% in the 3rd quarter. Sigma Investment Counselors Inc. now owns 16,353 shares of the company’s stock valued at $3,681,000 after buying an additional 123 shares during the last quarter. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Cencora

In other news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the completion of the transaction, the chairman now owns 285,088 shares of the company’s stock, valued at $67,223,750.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the completion of the transaction, the chairman now owns 285,088 shares of the company’s stock, valued at $67,223,750.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Silvana Battaglia sold 1,473 shares of the business’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total transaction of $357,482.37. Following the completion of the transaction, the executive vice president now directly owns 10,948 shares of the company’s stock, valued at $2,656,970.12. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 4,461,153 shares of company stock valued at $1,073,075,720 in the last 90 days. 15.80% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Leerink Partners lowered their price objective on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research report on Monday, October 7th. Evercore ISI lowered their price objective on shares of Cencora from $270.00 to $250.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. JPMorgan Chase & Co. lifted their price objective on shares of Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a research report on Wednesday, August 21st. Bank of America reiterated a “neutral” rating and issued a $245.00 price objective (down from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Finally, Wells Fargo & Company lifted their price objective on shares of Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a research report on Thursday, August 1st. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and an average price target of $259.44.

Cencora Price Performance

Cencora stock opened at $234.47 on Friday. Cencora, Inc. has a one year low of $182.75 and a one year high of $247.66. The company has a debt-to-equity ratio of 3.93, a quick ratio of 0.55 and a current ratio of 0.89. The business has a fifty day moving average of $232.15 and a two-hundred day moving average of $230.81. The company has a market cap of $46.77 billion, a P/E ratio of 25.65, a price-to-earnings-growth ratio of 1.40 and a beta of 0.44.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.18 by $0.16. The business had revenue of $74.20 billion during the quarter, compared to the consensus estimate of $73.32 billion. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The business’s revenue was up 10.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.92 EPS. As a group, analysts predict that Cencora, Inc. will post 13.63 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 9th were paid a dividend of $0.51 per share. This represents a $2.04 annualized dividend and a dividend yield of 0.87%. The ex-dividend date of this dividend was Friday, August 9th. Cencora’s dividend payout ratio (DPR) is presently 22.32%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.